The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
TEMOBIC: A ANOCEF phase II study of BCNU and temozolomide (TMZ) combination prior to radiotherapy (RT) in anaplasic oligodendroglial gliomas (AOG).
O. L. Chinot
Honoraria - Schering-Plough
Research Funding - Schering-Plough
K. Hoang-Xuan
No relevant relationships to disclose
M. Fabbro
No relevant relationships to disclose
L. Taillandier
No relevant relationships to disclose
J. Honnorat
No relevant relationships to disclose
M. Barrie
No relevant relationships to disclose
M. Sanson
No relevant relationships to disclose
C. Kerr
No relevant relationships to disclose
P. Beauchesne
No relevant relationships to disclose
S. Cartalat-Carel
No relevant relationships to disclose
D. Autran
No relevant relationships to disclose
A. Loundou
No relevant relationships to disclose
R. Guillevin
No relevant relationships to disclose
K. Mokhtari
No relevant relationships to disclose
D. Figarella-Branger
No relevant relationships to disclose
J. Delattre
No relevant relationships to disclose